Brokers Offer Predictions for Axon Enterprise Q3 Earnings

Axon Enterprise, Inc (NASDAQ:AXON) – Research analysts at Northland Securities raised their Q3 2026 earnings per share (EPS) estimates for shares of Axon Enterprise in a report issued on Thursday, August 6th. Northland Securities analyst M. Latimore now expects that the biotechnology company will earn $1.01 per share for the quarter, up from their previous forecast of $0.85. The consensus estimate for Axon Enterprise’s current full-year earnings is $2.04 per share. Northland Securities also issued estimates for Axon Enterprise’s Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $3.12 EPS, Q1 2027 earnings at $0.81 EPS, Q2 2027 earnings at $1.28 EPS, Q3 2027 earnings at $1.70 EPS, Q4 2027 earnings at $2.70 EPS and FY2027 earnings at $6.49 EPS.

AXON has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price objective on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Needham & Company LLC reissued a “buy” rating on shares of Axon Enterprise in a report on Thursday, August 6th. Morgan Stanley raised their target price on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Finally, TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, July 22nd. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus target price of $730.92.

Axon Enterprise Stock Performance

Shares of AXON opened at $604.32 on Monday. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The business has a 50-day simple moving average of $528.72 and a two-hundred day simple moving average of $473.44. The stock has a market cap of $49.09 billion, a price-to-earnings ratio of 250.76, a PEG ratio of 9.95 and a beta of 1.39. Axon Enterprise has a 52 week low of $339.01 and a 52 week high of $794.29.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same period last year, the firm earned $2.12 EPS. Axon Enterprise’s revenue for the quarter was up 35.3% compared to the same quarter last year.

Insider Transactions at Axon Enterprise

In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. The trade was a 4.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the transaction, the president directly owned 169,125 shares in the company, valued at approximately $82,609,106.25. This represents a 7.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 68,989 shares of company stock valued at $36,016,932. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors have recently added to or reduced their stakes in AXON. Brighton Jones LLC bought a new position in shares of Axon Enterprise during the fourth quarter worth $480,000. NewEdge Advisors LLC increased its holdings in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after acquiring an additional 668 shares during the last quarter. Empowered Funds LLC increased its holdings in Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after acquiring an additional 157 shares during the last quarter. Woodline Partners LP lifted its stake in Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in Axon Enterprise in the 2nd quarter worth $284,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.